Studies demonstrate that PRL-3, acting downstream of the VEGF/MEF2C pathway, recruits and enhances angiogenesis in endothelial cells in vitro and promotes tumor angiogenesis in vivo [47,110]. The gene discussed is PTP4A3; the disease is neoplasm.